The rockefeller university

Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors.

New research reveals how the RapA enzyme protects against R-loop cytotoxicity in E. coli.

She shares the award with three other scientists who together laid the groundwork for a new generation of drugs used to treat type 2 diabetes and obesity.